Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature
Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved..
Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases described in the literature. All patients but three resolved clinical picture with CCP. A dose from 200 to 800ml was enough in most cases. Antibody levels after transfusion were negative or low, suggesting consumption of them in SARS-CoV-2 neutralization. These patients have a protracted clinical course shortened after CCP. CCP could be helpful for patients with humoral immunodeficiency. It avoid relapses and chronification. CCP should be transfused as early as possible in patients with COVID-19 and humoral immunodeficiency.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica (English ed.) - 40(2022), 9 vom: 25. Nov., Seite 507-516 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Delgado-Fernández, Marcial [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Convalescent plasma |
|---|
| Anmerkungen: |
Date Completed 08.11.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimce.2021.01.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34850246X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34850246X | ||
| 003 | DE-627 | ||
| 005 | 20231226040406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eimce.2021.01.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM34850246X | ||
| 035 | |a (NLM)36336380 | ||
| 035 | |a (PII)S2529-993X(22)00200-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Delgado-Fernández, Marcial |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases described in the literature. All patients but three resolved clinical picture with CCP. A dose from 200 to 800ml was enough in most cases. Antibody levels after transfusion were negative or low, suggesting consumption of them in SARS-CoV-2 neutralization. These patients have a protracted clinical course shortened after CCP. CCP could be helpful for patients with humoral immunodeficiency. It avoid relapses and chronification. CCP should be transfused as early as possible in patients with COVID-19 and humoral immunodeficiency | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Convalescent plasma | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Humoral immunodeficiency | |
| 650 | 4 | |a Inmunodeficiencia humoral | |
| 650 | 4 | |a Obinutuzumab | |
| 650 | 4 | |a Plasma de convalecientes | |
| 650 | 4 | |a Rituximab | |
| 700 | 1 | |a García-Gemar, Gracia Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Fuentes-López, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Pérez, Manuel Isidro |e verfasserin |4 aut | |
| 700 | 1 | |a Oyonarte-Gómez, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Ruíz-García, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Carmona, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz-Cánovas, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Castaño-Carracedo, Manuel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Reguera-Iglesias, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Ruíz-Mesa, Juan Diego |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica (English ed.) |d 2012 |g 40(2022), 9 vom: 25. Nov., Seite 507-516 |w (DE-627)NLM220666776 |x 2529-993X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:9 |g day:25 |g month:11 |g pages:507-516 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimce.2021.01.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 9 |b 25 |c 11 |h 507-516 | ||